Candoxatril

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317365

CAS#: 118785-03-8

Description: Candoxatril is the orally active prodrug of candoxatrilat (UK-73967) human neutral endopeptidase (Neprilysin) as the neutral endopeptidase 24.11 complexed (RB-101) with phosphoramidon degrades and inactivates a number of bioactive peptides. Two multiply connected folding domains of the neutral endopeptidase locus splicing of exons 1, 2a, or 2b to the common exon 3 composed of 24 exons of the human CALLA/NEP gene containing the active site, it is known as peptidase family M13 the gluzincins a faint but significant structural relationship of the metzincins to the thermolysin-like enzymes, Zincin is the simplest descriptor of biological space.


Chemical Structure

img
Candoxatril
CAS# 118785-03-8

Theoretical Analysis

MedKoo Cat#: 317365
Name: Candoxatril
CAS#: 118785-03-8
Chemical Formula: C29H41NO7
Exact Mass: 515.29
Molecular Weight: 515.640
Elemental Analysis: C, 67.55; H, 8.01; N, 2.72; O, 21.72

Price and Availability

Size Price Availability Quantity
1g USD -1
2g USD -1
5g USD -1
Bulk inquiry

Synonym: UK 79300, UK-79300, UK79300, Candoxatril

IUPAC/Chemical Name: 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid

InChi Key: ZTWZVMIYIIVABD-RZMWZJFBSA-N

InChi Code: InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21?,23-,24?/m0/s1

SMILES Code: O=C(C1CCC(NC(C2(C[C@@H](COCCOC)C(OC3=CC4=C(CCC4)C=C3)=O)CCCC2)=O)CC1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 515.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Singh JS, Lang CC. Angiotensin receptor-neprilysin inhibitors: clinical
potential in heart failure and beyond. Vasc Health Risk Manag. 2015 Jun
1;11:283-95. doi: 10.2147/VHRM.S55630. eCollection 2015. Review. PubMed PMID:
26082640; PubMed Central PMCID: PMC4459540.


2: Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin
system inhibition for the treatment of heart failure. JACC Heart Fail. 2014
Dec;2(6):663-70. doi: 10.1016/j.jchf.2014.09.001. Epub 2014 Oct 8. Review. PubMed
PMID: 25306450.


3: Eizenberg Y, Grossman E, Peleg E, Shabtai Z, Sharabi Y. Neutral endopeptidase
inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the
metabolic syndrome. J Am Soc Hypertens. 2014 Apr;8(4):227-31. doi:
10.1016/j.jash.2014.01.006. Epub 2014 Jan 24. PubMed PMID: 24560177.